What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1326295

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1326295

Asia-Pacific Blood Glucose Monitoring Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

PAGES: 164 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The Asia-Pacific Blood Glucose Monitoring Market size is estimated at USD 4 billion in 2023, and is expected to reach USD 5.14 billion by 2028, growing at a CAGR of 7.69% during the forecast period (2023-2028).

Asia-Pacific has countries with the highest diabetic populations, such as China and India, with an average prevalence rate of more than 8.5%. Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices. Obesity is also considered one of the major factors contributing to the disease condition, mainly type 2 diabetes. Also, other factors such as technological innovations and advances provide convenience in measuring blood glucose levels. These devices help in the early detection of hypo- and hyperglycemic conditions, which tend to drive the market for glucose monitoring market.

APAC Blood Glucose Monitoring Market Trends

Self-monitoring Blood Glucose Devices Accounted for a Major Market Share in the current year

Although CGM is an advanced method for people living with diabetes to check glucose readings in real-time, SMBGs are the most preferred devices by patients in Asia-Pacific due to their economic affordability and lesser sophistication in usage when compared to CGM. The SMBG segment occupies more than 75% of the market share in the Asia-Pacific blood glucose monitoring market. Based on the component, disposable consumables (test strips and lancets) occupy the largest market share compared to glucometer devices. China and India rank high in terms of diabetic populations around the globe. The diabetes market is expected to increase at a high rate in these two countries during the forecast period. Although CGM provides real-time patient blood glucose data, its adaptability is very low in Asia-Pacific markets. The cost factor is a major concern for the low growth of CGM in the Asia-Pacific market. When a patient uses a blood glucose meter to check their levels, this is known as self-monitoring blood glucose (SMBG). The best method for diagnosing and treating hypoglycemia is SMBG. It can offer feedback on the effects of programs promoting healthy behavior and antihyperglycemic drug therapies.

Around 227 million individuals in the Asia-Pacific region contain type 2 diabetes, and nearly half of them are misdiagnosed and uninformed that they may experience long-term consequences, according to the OECD iLibrary. According to data from the International Diabetes Federation, the number of adults in South-East Asia (SEA) with diabetes is expected to rise from 90 million in 2021 to 113 million in 2030 and 152 million in 2045.

Asia-Pacific Blood Glucose Monitoring Market - IMG1

China Accounted for a Major Share in the Asia-Pacific Market in the current year

China is facing the largest diabetes epidemic in the world, with around 10% of its population suffering from metabolic illness, while nearly 37% are pre-diabetic. In 2020, China held the largest share in the Asia-Pacific blood glucose monitoring market due to the large patient pool and wide acceptance of advanced technologies. In China, currently, more than 12 million people are with type-1 diabetes, and 114 million people are with type-2 diabetes. Type 1 diabetes can be characterized as insulin-requiring. In contrast, Type 2 diabetes can be characterized as insulin-dependent diabetes, and type-1 diabetes patients need to check their blood glucose levels frequently, driving the China blood glucose devices market. The largest market share and the contributor to the global diabetes medicine market are both held by China. There are now a lot more companies in the nation making generic medications. The dominant international businesses in the sector under study are also up against fierce regional rivalry.

Modern continuous glucose monitoring systems may download the data and display patterns in blood glucose levels, or they can show glucose levels in real-time on receiver displays. With new technologies, such as mobile phone integration, continuous glucose monitoring devices are becoming more affordable, projected to drive the market.

Asia-Pacific Blood Glucose Monitoring Market - IMG2

APAC Blood Glucose Monitoring Industry Overview

The Asia-Pacific Blood Glucose Monitoring Market is moderately fragmented, with few major manufacturers, including a presence in major countries of the Asia-Pacific market. In contrast, the remaining manufacturers stayed confined to the other local or region-specific markets. Mergers and acquisitions between players in the recent past helped companies strengthen their market presence.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 49054



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Self-monitoring Blood Glucose Devices
    • 5.1.1 Glucometer Devices
    • 5.1.2 Test Strips
    • 5.1.3 Lancets
  • 5.2 Continuous Glucose Monitoring Devices
    • 5.2.1 Sensors
    • 5.2.2 Durables
  • 5.3 Geography
    • 5.3.1 Japan
    • 5.3.2 South Korea
    • 5.3.3 China
    • 5.3.4 India
    • 5.3.5 Australia
    • 5.3.6 Vietnam
    • 5.3.7 Malaysia
    • 5.3.8 Indonesia
    • 5.3.9 Philippines
    • 5.3.10 Thailand
    • 5.3.11 Rest of Asia-Pacific


  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population


  • 7.1 Company Profiles
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Roche
    • 7.1.3 Dexcom
    • 7.1.4 Medtronic
    • 7.1.5 Johnson and Johnson (Lifescan)
    • 7.1.6 Arkray
    • 7.1.7 Ascensia Diabetes Care
    • 7.1.8 Agamatrix Inc.
    • 7.1.9 Bionime Corporation
    • 7.1.10 Acon
    • 7.1.11 Medisana
    • 7.1.12 Trivida
    • 7.1.13 Rossmax
  • 7.2 Company Share Analysis
    • 7.2.1 Self-Monitoring Blood Glucose Devices
      • Abbott Diabetes Care
      • Roche
      • Others
    • 7.2.2 Continuous Glucose Monitoring Devices
      • Dexcom
      • Medtronic
      • Abbott Diabetes Care
      • others


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!